Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EML4-ALK Variant Affects ALK Resistance Mutations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2018

Früh Martin, Peters Solange

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ALK gene
Share to EML4 gene
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Oncogene Proteins, Fusion

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 29494260
DOI: 10.1200/JCO.2017.77.2764

Genes

ALK
EML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EML4-ALK Variant Affects ALK Resistance Mutations.PMID 29494260Read ↗

EML4-ALK Variants: Biological and Molecular Properties, and the Implications for PatientsSemantic proximity Read ↗

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the LiteratureSemantic proximity Read ↗

EML4-ALK: Update on ALK InhibitorsSemantic proximity Read ↗

EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC.Semantic proximity Read ↗

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFRSemantic proximity Read ↗

Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.Semantic proximity Read ↗

EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveriesSemantic proximity Read ↗

ALK gene alterations in cancer: biological aspects and therapeutic implications.Semantic proximity Read ↗

EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors.Semantic proximity Read ↗

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.Semantic proximity Read ↗

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsSemantic proximity Read ↗

Targeting drug-resistant mutations in ALK.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.